Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for CINV in Nasopharyngeal Carcinoma
NCT02933099Phase 3Unknown
- Start
- Oct 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms). Primary endpoint: Complete Response Rate of CINV up to 10 days. Status: unknown.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT02933099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933099.